Hemogenyx Pharmaceuticals Share Discussion Threads

[purple11] 20/12/2019 09:43

I cant see these manufacturability tests going wrong or taking that long,and well have news on their outcome to come.
then surely they'll be able to get the global pharma company to atleast pay for the monkey trials.

success in the monkey trials will provide a pretty sizeable spike and anyone wishing to exit should wait for that imo.

we need news on when these monkey trials will be starting.i cant see the global pharma company not paying for them,i doubt they cost that much.

this is weak because theres a lull in news and the market is worried about how they will pay for the trial.

a little bit of faith and give it 6months or so and we could be reading about a positive result in monkeys which will clearly spark a rocket here.patience and ignore the price tll then I say.i am reassured by what Adrian b had to say and that he hasn't sold any shares yet.

better days ahead!

[purple11] 19/12/2019 15:10

well atleast ppl are stopped from selling anymore then.

[jovi1] 19/12/2019 14:16

hope not but this is going down more on the short term as i cannot sell more that £100 in share at the moment no demand at all
hopefully better day ahead and clearly this type of company are only one good news away to make or brake

[purple11] 19/12/2019 10:37

shame theres no scappy buying to offset it!

[purple11] 19/12/2019 10:35

6.5m cap now.

id have thought 5m cap must be around the bottom if it gets there.then its up to HEMO.

is it just AIM dross or have they got something?

[johntopdog] 16/12/2019 23:00

Purple...I would have thought you would have known his name is Beeston not Beaston if you have been receiving such emails

[purple11] 13/12/2019 10:21

weve been emailing eachother since silf days. he doesn't work at hemo anymore so can say what he likes.im hoping he may have his ear to the ground still.hes certainly v confident.

[on target] 12/12/2019 16:21

Beeston is unlikely to email a total stranger with inside information, so I would guess - if you did receive an email - that he knows no more than the rest of us?

[dave4545] 12/12/2019 16:16

Maybe but do not log out as purple11 and then log back in as runawaypaul to try and deceive people eh !

[purple11] 12/12/2019 15:07

if the email proves correct they'll be multiple posts by multiple users flooding the bbs for days.don't shoot the messenger -this will rocket!

[dave4545] 12/12/2019 14:58

I thought you had gave up that lark of using multiple names paul ?

[runwaypaul] 12/12/2019 14:44

could be a perfect entry here if Beaston knows something we don't.

[purple11] 12/12/2019 14:35

he's not working for hemo anymore so can say what he likes I guess.maybe he still has an inside tac on what is going on.hope hes right.gl

[purple11] 12/12/2019 14:24

6p when news lands?

[purple11] 11/12/2019 15:31

just had an email from a beaston saying hes expecting the global pharma deal to land v shortly and to hang in there.hope hes right.he says he still hasn't sold a single share and is expecting big gains ahead.

[tsmith2] 25/11/2019 22:55

Agree the share price is just plain silly Should be a multiple

[johntopdog] 25/11/2019 22:52

An excellent presentation and most of it beyond me...but it all sounds very exciting and very promising and things are progressing well..share price ridiculous

[purple11] 25/11/2019 19:34

Presentation at Investival

[badger60] 25/11/2019 03:50

Good to see a bit of volume and share price increase, and hopefully it will continue this week. I think that there are not many willing sellers/freefloat at these levels, which should further enhance the share price

[purple11] 19/11/2019 15:46

sadly the whole market is completely dead atm.there is no real volume anywhere.

[on target] 18/11/2019 10:33

Investival showcase tomorrow do you mean?

[tsmith2] 18/11/2019 10:16

Should focus minds at oncology conference

[purple11] 18/11/2019 09:47

second phase global pharma deal


GlobalCo development agreement

Work with a global international pharmaceutical company ("GlobalCo") on the Company's CDX antibody ("CDX") as a clinical candidate, first announced on 14 May 2018, has entered its second phase. The Company and GlobalCo continue to develop CDX towards clinical readiness and have initiated manufacturability assessment and follow-up tests of the antibody.

Hemogenyx and GlobalCo remain optimistic as to the outcome of these tests based on results to date and look forward to providing further updates as the development work progresses.